

MW Pharma LTD ta NUBU Pharma

Disclosure Report Date Submitted: February 2024

© B Lab 2024



Disclosure Materials

Certified B Corporations must complete a Disclosure Questionnaire to identify potentially sensitive issues related to the company (e.g. historical fines, sanctions, material litigation, or sensitive industry practices).

This component does not affect the company's score on the B Impact Assessment. If the company answers affirmatively to any items in the Disclosure Questionnaire that B Lab deems relevant for public stakeholders, then, as a condition of their certification, the company must:

- Be transparent about details of the disclosure issues identified on the company's public B Impact Report
- 2) Describe how the company has addressed this issue
- 3) Demonstrate that management practices are in place to avoid similar issues from arising in the future, when necessary.

In all cases, the Standards Advisory council reserves the right to refuse certification if the company is ultimately deemed not to uphold the spirit and integrity of the community.

In addition to the voluntary indication of sensitive issues in the Disclosure Questionnaire, companies pursuing Certification also are subject to a background check by B Lab staff. Background checks include a review of public records, news sources, and search engines for company names, brands, executives/founders, and other relevant topics.

Sensitive issues identified through background checks may or may not be within the scope of questions in the Disclosure Questionnaire, but undergo the same review process and are subject to the same possible review by the Standards Advisory Council, including ineligibility for B Corp Certification, required remediation, or disclosure.

B Lab's Public Complaints Process

Any party may submit a complaint about a current B Corp through B Lab's Public Complaint Process. Grounds for complaint include:

- Intentional misrepresentation of practices, policies, and/or claimed outcomes during the company's certification process
- Breaches of the B Corp Community's core values as expressed in our Declaration of Interdependence

This document contains a copy of the company's completed Disclosure Questionnaire and related disclosure documentation provided by the company.



Disclosure Questionnaire

Industries and Products

Yes No Please indicate if the company is involved in production of or trade in any of the following. Select Yes for all options that **Animal Products or Services** $\boxed{}$ **Biodiversity Impacts** Chemicals $\boxed{}$ **Disclosure Alcohol Disclosure Firearms Weapons** $\boxed{}$ **Disclosure Mining** $\boxed{}$ **Disclosure Pornography** $\boxed{}$ **Disclosure Tobacco** $\boxed{}$ **Energy and Emissions Intensive** $\boxed{}$ Industries Fossil fuels \square Gambling **Genetically Modified Organisms** $\boxed{}$ Illegal Products or Subject to $\boxed{}$ **Phase Out** Industries at Risk of Human \square **Rights Violations Monoculture Agriculture** \square **Nuclear Power or Hazardous** $\overline{\mathbf{A}}$ **Materials** Payday, Short Term, or High **Interest Lending Water Intensive Industries** $\overline{\mathbf{A}}$ Tax Advisory Services

Outcomes & Penalties

	Yes	No	
Please indicate if the company has had any formal complaint to a regulatory agency or been assessed any fine or sanction in the past five years for any of the following practices or policies. Check all that apply.			
Anti-Competitive Behavior		\checkmark	
Breaches of Confidential Information		\checkmark	
Bribery, Fraud, or Corruption		\checkmark	
Company has filed for bankruptcy		\checkmark	
Consumer Protection		V	
Financial Reporting, Taxes, Investments, or Loans		N	
Hazardous Discharges Into Air/Land/Water (Past 5 Yrs)		\searrow	
Labor Issues		\checkmark	
Large Scale Land Conversion, Acquisition, or Relocation		N.	
Litigation or Arbitration			
On-Site Fatality		\searrow	
Penalties Assessed For Environmental Issues		N	
Political Contributions or International Affairs		\searrow	
Recalls	\checkmark		
Significant Layoffs		\checkmark	
Violation of Indigenous Peoples Rights		V	
Other		V	



Practices

	Yes	No
Please indicate if the following statements are true regarding whether or not the company engages in the following practices. Check all that apply. If the statement is true, select "Yes." If false, select "No."		
Animal Testing		\checkmark
Company/Suppliers Employ Under Age 15 (Or Other ILO Minimum Age)		V
Company prohibits freedom of association/collective bargaining		✓
Company workers are prisoners		\checkmark
Conduct Business in Conflict Zones		\checkmark
Confirmation of Right to Work		\checkmark
Does not transparently report corporate financials to government		\searrow
Employs Individuals on Zero-Hour Contracts		V
Facilities located in sensitive ecosystems		V
ID Cards Withheld or Penalties for Resignation		V
No formal Registration Under Domestic Regulations		V
No signed employment contracts for all workers		
Overtime For Hourly Workers Is Compulsory		
Payslips not provided to show wage calculation and deductions		N

	Yes	No
Sale of Data		V
Tax Reduction Through Corporate Shells		V
Workers cannot leave site during non-working hours		V
Workers not Provided Clean Drinking Water or Toilets		\searrow
Workers paid below minimum wage		N
Workers Under Bond		\checkmark
Other	\checkmark	

Supply Chain Disclosures

	Yes	No
Please indicate if any of the following statements are true regarding your company's significant suppliers.		
Business in Conflict Zones		\checkmark
Child or Forced Labor		\vee
Negative Environmental Impact		
Negative Social Impact		\vee
Other		\checkmark



Disclosure Questionnaire Statement

Disclosure Questionnaire Category: Other - Cannabis Related Products

Topic	Company involved in the sale of medicinal Cannabis.
Summary of Issue	MW Pharma imports and distributes medicinal cannabis in New Zealand. The company is not involved in the growing of Cannabis.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	In the last fiscal, 63% of the company's revenue was derived from the sale of medicinal Cannabis.
Impact on Stakeholders	Companies serving clients in controversial industries have the potential to further the negative social and / or environmental impacts of the controversial industry.
	Cannabis and cannabis-related products are subject to controversy because of their historic and evolving legal status, as well as concerns about the potential harm that the products may cause. Companies involved with cannabis products are eligible for B Corp Certification depending on a variety of factors, including their legal status and whether they produce products designed for medical or recreational use.
Implemented Management Practices	The company complies with all relevant laws and regulations dictated by the Medical Cannabis Agency, Med Safe (NZ Ministry of Health) for the production and sale of its cannabis-related products and have licenses to demonstrate their medicinal Cannabis sales.
	In order to ensure that their Cannabis sales are strictly verified to be for medical purposes only, MW Pharma has a service based standard operating procedures to support processing and distributing. Products are reviewed by the Regulatory agency before sale and audits as part of their licensing requirements. It is standard operating procedure to require license checks at the pharmacy level at the time that new customers sign up.



Disclosure Questionnaire Statement

Disclosure Questionnaire Category: Recalls

Issued Date	April 2020
Topic	Recalls due to incorrect labeling
Summary of Issue	The company has had 1 material recall over the last years due to incorrect labeling on its TheraLeaf products, including an incorrect strength of the product on the packaging as well as cosmetic damage of boxes. In response to a complaint received by a dispensing pharmacy client, MW Pharma's management visited the partner distribution center (ProPharma) to physically check the remaining stock and discovered more issues. Medsafe advised the company to carry out a Class I Recall of products. The product is no longer available as new government regulations came into effect causing the product to not meet new standards.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	510 units were recalled representing 100% of the company's production across all company products in FY2020.
Impact on Stakeholders	Products did not reach consumers and did not represent a risk of damage. However, this recall could have caused delays to patients getting their medication.
Resolution	All products recalled, received and destroyed.
Implemented Management Practices	 Summary of Final Recall Actions All TheraLeaf stock that was affected by this product recall has been securely destroyed by Interwaste. MW Pharma and Dragonfly CAPA reports outlined the cause of the issues, and documented the steps taken to rectify it. Additional checks and procedures have been implemented to ensure an issue like this can not be repeated.
Report	Recall Notice TheraLeaf Products
Related Incidents	None